Back
Compare AU
Compare XALG vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Alphinity Global Equity Fund - Active ETF (XALG) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
XALG | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 1 | 73 |
Median incremental investment | $751.00 | $660.00 |
Median investment frequency | Daily | Monthly |
Median total investment | $506.00 | $1,696.50 |
Average age group | 26 - 35 | > 35 |
Key Summary
XALG | CURE | |
|---|---|---|
Strategy | XALG.AX was created on 2015-12-21 by Alphinity. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to outperform its benchmark after costs and over rolling three-year periods. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Microsoft Corp (5.91 %) NVIDIA Corp (5.03 %) Netflix Inc (4.10 %) | Avidity Biosciences Inc Ordinary Shares (2.45 %) Revolution Medicines Inc Ordinary Shares (2.36 %) Insmed Inc (2.14 %) |
Top 3 industries | Information Technology (40.61 %) Financials (25.24 %) Communication Services (16.73 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0.75 % | 0.45 % |
Key Summary
XALG | CURE | |
|---|---|---|
Issuer | Alphinity | Global X |
Tracking index | S&P Biotechnology Select Industry | |
Asset class | ETF | ETF |
Management fee | 0.75 % | 0.45 % |
Price | $10.95 | $59.82 |
Size | N/A | $38.099 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 6.26 % | 5.08 % |
Market | ASX | ASX |
First listed date | 16/01/2023 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
XALG | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 1 | 73 |
Median incremental investment | $751.00 | $660.00 |
Median investment frequency | Daily | Monthly |
Median total investment | $506.00 | $1,696.50 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
XALG | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
XALG | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |